Analysts at Mizuho Securities Reconfirmed their Sell rating for Eagle Pharmaceuticals (EGRX) with $40.0000 Target Price per Share; Restore plc (LON:RST) Had 5 Bullish Analysts

May 7, 2018 - By Peter Erickson

In a research report released on today, Mizuho Securities kept their Sell rating on Eagle Pharmaceuticals (NASDAQ:EGRX)‘s stock. The target means a potential downside of -28.71% from firm’s last stock close price.

Among 5 analysts covering Restore PLC (LON:RST), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Restore PLC had 41 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Buy” rating by Peel Hunt on Wednesday, July 27. The rating was maintained by Peel Hunt with “Buy” on Thursday, March 9. The firm earned “Buy” rating on Thursday, January 5 by Peel Hunt. The firm has “Buy” rating by Peel Hunt given on Thursday, January 4. The company was maintained on Thursday, April 7 by Peel Hunt. Peel Hunt maintained it with “Add” rating and GBX 608 target in Monday, March 26 report. On Tuesday, January 26 the stock rating was maintained by Peel Hunt with “Buy”. The firm has “Buy” rating by Peel Hunt given on Monday, May 22. N+1 Singer maintained the stock with “Buy” rating in Wednesday, August 5 report. The firm earned “Add” rating on Tuesday, March 13 by Peel Hunt. See Restore plc (LON:RST) latest ratings:

27/04/2018 Broker: Liberum Capital Rating: Buy New Target: GBX 660.00 Initiates Starts
26/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 585.00 New Target: GBX 620.00 Reiteration
26/03/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 608.00 New Target: GBX 608.00 Maintain
16/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 585.00 New Target: GBX 585.00 Maintain
13/03/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 608.00 New Target: GBX 608.00 Maintain
30/01/2018 Broker: Peel Hunt Rating: Add New Target: GBX 608.00 Maintain
23/01/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 528.00 New Target: GBX 608.00 Lowers
04/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 528.00 New Target: GBX 528.00 Maintain

It closed at GBX 571 lastly. It is down 0.00% since May 7, 2017 and is . It has underperformed by 11.55% the S&P500.

Restore plc, together with its subsidiaries, operates as a support services firm primarily in the United Kingdom. The company has market cap of 649.90 million GBP. The firm operates through two divisions, Document Management and Relocation. It has a 85.22 P/E ratio. The Document Management segment stores and retrieves hard copy documents stored in cardboard boxes; manages archive boxes of document files, magnetic data, films, and other materials for blue-chip organizations; and offers reorganization of customer documents, document restoration, file-tracking, and electronic data back-up services, as well as offers cloud storage that allows access to indexed records.

Investors sentiment increased to 1.61 in 2017 Q4. Its up 0.35, from 1.26 in 2017Q3. It improved, as 10 investors sold Restore plc shares while 21 reduced holdings. 20 funds opened positions while 30 raised stakes. 15.17 million shares or 1.48% less from 15.40 million shares in 2017Q3 were reported. Jpmorgan Chase And Company has invested 0% in Restore plc (LON:RST). State Board Of Administration Of Florida Retirement holds 0% of its portfolio in Restore plc (LON:RST) for 13,738 shares. Vnbtrust National Association holds 492,415 shares or 3.58% of its portfolio. Menta Cap Ltd Liability Company has invested 0.27% of its portfolio in Restore plc (LON:RST). 403,848 were accumulated by Roumell Asset Management Lc. Schwab Charles Investment Mngmt holds 0% of its portfolio in Restore plc (LON:RST) for 59,068 shares. Rhumbline Advisers has 17,152 shares. Dimensional Fund Advsr L P accumulated 321,431 shares. Macquarie Grp Inc Ltd owns 0% invested in Restore plc (LON:RST) for 29,037 shares. Ameriprise reported 18,237 shares. Oberweis Asset Management owns 89,400 shares for 0.26% of their portfolio. 11,421 are held by Gp. Thompson Siegel And Walmsley Limited Liability reported 2,500 shares. Meeder Asset Incorporated has 0% invested in Restore plc (LON:RST) for 2,648 shares. State Street Corporation reported 286,685 shares stake.

Another recent and important Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news was published by Streetinsider.com which published an article titled: “Eagle (EGRX) Denied Unique Ryanodex J-Code – Mizuho” on May 07, 2018.

The stock increased 0.21% or $0.12 during the last trading session, reaching $56.11. About 180,447 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 36.05% since May 7, 2017 and is downtrending. It has underperformed by 47.60% the S&P500.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on May, 14. They expect $0.81 earnings per share, down 42.96% or $0.61 from last year’s $1.42 per share. EGRX’s profit will be $12.01 million for 17.32 P/E if the $0.81 EPS becomes a reality. After $0.84 actual earnings per share reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -3.57% negative EPS growth.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma has $119 highest and $37.0 lowest target. $71.75’s average target is 27.87% above currents $56.11 stock price. Eagle Pharma had 24 analyst reports since July 29, 2015 according to SRatingsIntel. Mizuho maintained the shares of EGRX in report on Monday, December 18 with “Sell” rating. On Thursday, November 3 the stock rating was upgraded by Mizuho to “Buy”. The firm has “Sell” rating by Mizuho given on Thursday, October 26. As per Monday, October 2, the company rating was maintained by RBC Capital Markets. Mizuho downgraded Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Monday, January 9 to “Underperform” rating. As per Monday, February 26, the company rating was maintained by Mizuho. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. The firm has “Sell” rating given on Wednesday, March 21 by Mizuho. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Neutral” rating by Mizuho on Wednesday, November 16. The rating was maintained by Mizuho on Friday, February 26 with “Buy”.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>